Description
Phenibut HCl
Phenibut hydrochloride (HCl) is a psychoactive compound studied for its effects on the central nervous system. It is structurally related to gamma-aminobutyric acid (GABA) and has been used medically in some countries, but it is not an FDA-approved medicine in the United States. Its potential for tolerance, dependence, and withdrawal makes safety a central consideration.
How It Works
Phenibut has activity involving GABA-related signaling, particularly GABA-B receptors. Its central nervous system effects can influence alertness, anxiety-related responses, and sedation. The full pharmacological profile and risks depend on exposure and individual factors.
POTENTIAL RESEARCH INTEREST
- GABA-related signaling: Investigated for its activity at inhibitory neurotransmitter pathways.
- Neuropharmacology: Studied for its effects on central nervous system function.
- Tolerance and dependence: Relevant to research on adaptation following repeated exposure.
- Withdrawal mechanisms: Examined in reports involving discontinuation after prolonged use.
Side Effects and Safety
Phenibut can cause sedation, impaired coordination, confusion, and other adverse effects. Repeated use can lead to dependence, and withdrawal may be severe. Combining it with alcohol, opioids, sedatives, or other central nervous system depressants can increase risk. Abruptly stopping after regular use can also be dangerous.
Dosage
This page does not provide a self-use dosing schedule. There is no FDA-approved US labeling establishing a safe human-use regimen for Phenibut HCl.
Handling & Safety
Keep accurate material records and follow applicable laboratory requirements. It should not be treated as an ordinary dietary supplement.
Where to Find Phenibut HCl
IML provides research information and links to independent suppliers. The selected supplier handles sales and fulfillment.
Affiliate Disclosure: IronMountainLabz does not sell or ship Phenibut HCl. Links on this page may direct readers to independent suppliers through affiliate links.
